Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/06/28/2695973/0/en/Neuronascent-to-Present-New-Parkinson-s-Model-Data-at-AAIC-2023-for-the-Alzheimer-s-Disease-Investigational-Therapy-NNI-362.html
https://www.globenewswire.com/news-release/2022/11/08/2550583/0/en/Neuronascent-to-Present-Further-NNI-362-Phase1a-Data-at-CTAD-2022-for-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2022/06/01/2453975/0/en/Neuronascent-Receives-FDA-Orphan-Drug-Designation-for-NNI-351-Treatment-of-Fragile-X-Syndrome.html
https://www.globenewswire.com/news-release/2022/05/24/2449058/0/en/Neuronascent-Receives-FDA-Rare-Pediatric-Drug-Designation-for-NNI-351-Treatment-for-Fragile-X-Syndrome.html
https://www.globenewswire.com/news-release/2022/03/30/2412617/0/en/Neuronascent-Releases-Further-Positive-Results-of-NNI-362-in-A-Randomized-Phase-1a-Trial-for-Alzheimer-s-Disease.html